- Conditions
- Pancreatic Cancer, Neoplasm Metastasis
- Interventions
- Capecitabine, OSI-774
- Drug
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2008
- U.S. locations
- 3
- States / cities
- Boston, Massachusetts
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 601–624
of 1,396
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Advanced Non-small Cell Lung Cancer
- Interventions
- Atezolizumab
- Drug
- Lead sponsor
- Liza Villaruz, MD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2022
- U.S. locations
- 2
- States / cities
- Orlando, Florida • Pittsburgh, Pennsylvania
- Conditions
- Cervical Cancer, Cervical Cancer Recurrent, Cervical Cancer Metastatic
- Interventions
- Stereotactic body radiation therapy (SBRT), Atezolizumab
- Radiation · Drug
- Lead sponsor
- H. Lee Moffitt Cancer Center and Research Institute
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2028
- U.S. locations
- 2
- States / cities
- Tampa, Florida • Hilliard, Ohio
- Conditions
- DLBCL, Lymphoma, B-Cell
- Interventions
- Polatuzumab vedotin, Rituximab, Cyclophosphamide, Doxorubicin, Prednisone
- Drug
- Lead sponsor
- University of Rochester
- Other
- Eligibility
- 75 Years and older
- Enrollment
- 39 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 1
- States / cities
- Rochester, New York
- Conditions
- Pleural Effusion
- Interventions
- Cathflo Activase, Talc Slurry Pleurodesis
- Drug
- Lead sponsor
- Memorial Healthcare System
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 1
- States / cities
- Hollywood, Florida
- Conditions
- Rheumatoid Arthritis
- Interventions
- GDC-0853
- Drug
- Lead sponsor
- Genentech, Inc.
- Industry
- Eligibility
- 18 Years to 76 Years
- Enrollment
- 496 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2019
- U.S. locations
- 11
- States / cities
- Glendale, Arizona • Covina, California • El Cajon, California + 7 more
- Conditions
- Lymphoma
- Interventions
- Avastin, Rituximab
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 13 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2004 – 2007
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Age Related Macular Degeneration
- Interventions
- Ranibizumab
- Drug
- Lead sponsor
- Vitreous -Retina- Macula Consultants of New York
- Other
- Eligibility
- 50 Years and older
- Enrollment
- 9 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2010 – 2012
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Non-Hodgkin Lymphoma
- Interventions
- Mosunetuzumab (Cohorts A-C), Mosunetuzumab (Cohorts D-E), Tocilizumab
- Drug
- Lead sponsor
- Genentech, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 320 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 39
- States / cities
- Mobile, Alabama • Anchorage, Alaska • Phoenix, Arizona + 34 more
- Conditions
- Ovarian Cancer, Basal Cell Carcinoma, Metastatic Colorectal Cancer
- Interventions
- Vismodegib, FOLFOX, FOLFIRI, Bevacizumab
- Drug
- Lead sponsor
- Genentech, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2014
- U.S. locations
- 10
- States / cities
- Scottsdale, Arizona • Oakland, California • Palm Springs, California + 7 more
- Conditions
- Obesity
- Interventions
- recombinant human growth hormone (rhGH), Placebo
- Drug
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 13 Years to 21 Years · Female only
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2014
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Chronic Obstructive Pulmonary Disease
- Interventions
- Astegolimab, Placebo
- Drug
- Lead sponsor
- Genentech, Inc.
- Industry
- Eligibility
- 40 Years to 90 Years
- Enrollment
- 1,334 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 36
- States / cities
- Dothan, Alabama • Jasper, Alabama • Mobile, Alabama + 32 more
- Conditions
- Triple Negative Breast Cancer, Stage IV Breast Cancer, HER2 Negative, Invasive Breast Cancer
- Interventions
- Atezolizumab, Carboplatin, Laboratory Biomarker, Quality-of-Life Assessment
- Drug · Other
- Lead sponsor
- Vanderbilt-Ingram Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 106 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2023
- U.S. locations
- 6
- States / cities
- Washington D.C., District of Columbia • Indianapolis, Indiana • Baltimore, Maryland + 3 more
- Conditions
- Solid Tumors, Adult
- Interventions
- VB10.NEO
- Biological
- Lead sponsor
- Nykode Therapeutics ASA
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 5
- States / cities
- San Francisco, California • New Haven, Connecticut • Louisville, Kentucky + 2 more
- Conditions
- CDK Gene Mutation, Metastatic Malignant Neoplasm in the Brain, Metastatic Malignant Solid Neoplasm, NTRK Family Gene Mutation, PI3K Gene Mutation, ROS1 Gene Mutation, KRAS G12C Mutation
- Interventions
- Abemaciclib, PI3K Inhibitor paxalisib, Entrectinib, Adagrasib
- Drug
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2028
- U.S. locations
- 435
- States / cities
- Anchorage, Alaska • Phoenix, Arizona • Scottsdale, Arizona + 306 more
- Conditions
- Locally Advanced Solid Tumors, Recurrent Solid Tumors, Metastatic Solid Tumors
- Interventions
- RO7566802, Atezolizumab
- Drug
- Lead sponsor
- Genentech, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 65 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 6
- States / cities
- Birmingham, Alabama • New Haven, Connecticut • New York, New York + 3 more
- Conditions
- Breast Cancer
- Interventions
- Trastuzumab, Bevacizumab, Docetaxel
- Drug
- Lead sponsor
- Bhuvaneswari Ramaswamy
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2017
- U.S. locations
- 3
- States / cities
- Cleveland, Ohio • Columbus, Ohio • Pittsburgh, Pennsylvania
- Conditions
- Multiple Sclerosis
- Interventions
- Gadoteridol
- Drug
- Lead sponsor
- University of Maryland, Baltimore
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2023
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Aggressive Non-Hodgkin Lymphoma, ALK-Positive Large B-Cell Lymphoma, Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements, High Grade B-Cell Lymphoma, Not Otherwise Specified, Primary Mediastinal Large B-Cell Lymphoma, T-Cell/Histiocyte-Rich Large B-Cell Lymphoma, Gray-Zone Lymphoma
- Interventions
- Polatuzumab Vedotin, Rituximab, Prednisone, Etoposide, Doxorubicin, Cyclophosphamide, Glofitamab, Multigated Acquisition Scan, Echocardiography Test, FDG-Positron Emission Tomography, Computed Tomography, Bone Marrow Biopsy, Biospecimen Collection, Bone Marrow Aspiration
- Drug · Biological · Procedure
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 56 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2031
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Healthy Volunteers
- Interventions
- ZN-A-1041 Formulation 1, ZN-A-1041 Formulation 2, Rabeprazole
- Drug
- Lead sponsor
- Genentech, Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025
- U.S. locations
- 2
- States / cities
- Daytona Beach, Florida • Dallas, Texas
- Conditions
- Breast Cancer
- Interventions
- Herceptin, Taxol, Adriamycin, Cytoxan
- Drug
- Lead sponsor
- Harold J. Burstein, MD, PhD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 41 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1999 – 2012
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts
- Conditions
- Bullous Pemphigoid
- Interventions
- Omalizumab, prednisone
- Drug
- Lead sponsor
- University of Iowa
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2010
- U.S. locations
- 1
- States / cities
- Iowa City, Iowa
- Conditions
- Cytomegalovirus Infections
- Interventions
- MCMV3068A, MCMV5322A, Placebo
- Drug
- Lead sponsor
- Genentech, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 122 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 15
- States / cities
- Los Angeles, California • San Diego, California • San Francisco, California + 10 more
- Conditions
- Chronic Rhinosinusitis With Nasal Polyps, Nasal Polyps
- Interventions
- Omalizumab
- Biological
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 2
- States / cities
- Baltimore, Maryland